|
1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1): 271-89. 2. Almasi Z, Mohammadian-Hafshejani A, Salehiniya H. Incidence, mortality, and epidemiological aspects of cancers in Iran; differences with the world data. J BUON 2016; 21(4): 994-1004. 3. Hassanipour S, Fathalipour M, Salehiniya H. The incidence of prostate cancer in Iran: a systematic review and meta-analysis. Prostate Int 2018; 6(2): 41-45. 4. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147(3 Pt 2): 817-21. 5. Pokorny M, Van de Ven W, Barentsz J, Thompson L. Reply to Yaalini Shanmugabavan, Stephanie Guillaumier and Hashim U. Ahmed's letter to the editor re: Morgan R. Pokorny, Maarten de Rooij, Earl Duncan, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2015; 67(3): e54-5. 6. Tan TW, Png KS, Lee CH, Yuwono A, Yeow Y, Chong KT, et al. MRI Fusion-Targeted Transrectal Prostate Biopsy and the Role of Prostate-Specific Antigen Density and Prostate Health Index for the Detection of Clinically Significant Prostate Cancer in Southeast Asian Men. J Endourol 2017; 31(11): 1111-6. 7. Thompson J, Lawrentschuk N, Frydenberg M, Thompson L, Stricker P; USANZ. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int 2013; 112 Suppl 2: 6-20. 8. Liddell H, Jyoti R, Haxhimolla HZ. mp-MRI Prostate Characterised PIRADS 3 Lesions are Associated with a Low Risk of Clinically Significant Prostate Cancer - A Retrospective Review of 92 Biopsied PIRADS 3 Lesions. Curr Urol 2015; 8(2): 96-100. 9. Sathianathen NJ, Omer A, Harriss E, Davies L, Kasivisvanathan V, Punwani S, et al. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. Eur Urol 2020; 78(3): 402-14. 10. Ghane Z, Faeghi F, Ghafoori M, Payandeh A. Multiparametric MRI for the Diagnosis of Tumor Type in Patients Suspicious of Inner Gland Prostate Cancer. Urol J 2019; 16(6): 552-7. 11. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016; 69(1): 16-40. 12. Filson CP, Natarajan S, Margolis DJ, Huang J, Lieu P, Dorey FJ, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer 2016; 122(6): 884-92. 13. Costa MJ, Delingette H, Novellas S, Ayache N. Automatic segmentation of bladder and prostate using coupled 3D deformable models. Med Image Comput Comput Assist Interv 2007;10(Pt 1):252-60. 14. Schoots IG. MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? Transl Androl Urol 2018; 7(1): 70-82. 15. Borkowetz A, Platzek I, Toma M, Renner T, Herout R, Baunacke M, et al. Evaluation of Prostate Imaging Reporting and Data System Classification in the Prediction of Tumor Aggressiveness in Targeted Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy. Urol Int 2017; 99(2): 177-85. 16. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 2018; 378(19): 1767-77. 17. Cash H, Maxeiner A, Stephan C, Fischer T, Durmus T, Holzmann J, et al. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy. World J Urol 2016; 34(4): 525-32. 18. Benelli A, Vaccaro C, Guzzo S, Nedbal C, Varca V, Gregori A. The role of MRI/TRUS fusion biopsy in the diagnosis of clinically significant prostate cancer. Ther Adv Urol 2020; 12: 1756287220916613. 19. Hassanipour-Azgomi S, Mohammadian-Hafshejani A, Ghoncheh M, Towhidi F, Jamehshorani S, Salehiniya H. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate Int 2016; 4(3): 118-24. 20. Pakzad R, Rafiemanesh H, Ghoncheh M, Sarmad A, Salehiniya H, Hosseini S, et al. Prostate Cancer in Iran: Trends in Incidence and Morphological and Epidemiological Characteristics. Asian Pac J Cancer Prev 2016; 17(2): 839-43. 21. Liu T, Mendes DE, Berkman CE. Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells. Int J Oncol 2014; 44(3): 918-22. 22. Porcaro AB, Tafuri A, Sebben M, Novella G, Processali T, Pirozzi M, et al. Elevated prostate volume index and prostatic chronic inflammation reduce the number of positive cores at first prostate biopsy set: results in 945 consecutive patients. Int Braz J Urol 2020; 46(4): 545-56. 23. Yilmaz H, Ustuner M, Ciftci S, Yavuz U, Ozkan TA, et al. Prostate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive (≥ct2) patients. Int Braz J Urol 2014; 40(5): 613-9.
|
.png){kind=logo}
